Protara Therapeutics (NASDAQ:TARA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.